Abiraterone 250 mg is an oral tablet containing 250 mg of abiraterone acetate. Abiraterone acetate is a prodrug that is converted to abiraterone in the body. Abiraterone inhibits CYP17, an enzyme involved in androgen production.
Product identity
| Attribute | Information |
|---|---|
| Generic name | Abiraterone acetate |
| Active moiety | Abiraterone |
| Strength | 250 mg |
| Dosage form | Tablet |
| Route | Oral |
| Drug class | CYP17 inhibitor |
| Therapeutic area | Prostate cancer |
| Reference product | Zytiga |
| Specific product manufacturer | – |
Abiraterone acetate versus abiraterone
The marketed tablet contains abiraterone acetate, while abiraterone is the active substance generated after conversion in the body. This distinction explains why the medicine is commonly called “abiraterone acetate” in prescribing information even though patients and medical literature often refer to it simply as abiraterone.
Abiraterone and Zytiga
Zytiga is the established reference medicine containing abiraterone acetate. Generic abiraterone products may be authorized through regulatory pathways requiring demonstration of pharmaceutical quality and, where applicable, bioequivalence to the reference product.
Product-specific information
The exact manufacturer, marketing authorization holder, country of authorization and packaging for a particular Abiraterone 250 mg product must be established from its official documentation.
Why supervision is necessary
Abiraterone affects steroid hormone synthesis and can produce mineralocorticoid-related effects and liver toxicity. Its use therefore involves more than simply taking a tablet; appropriate corticosteroid therapy, androgen-deprivation therapy where applicable and monitoring form part of the treatment context.